GU Cancers Symposium 2014 - Open-label, phase II RAPTOR study of everolimus for papillary mRCC: Efficacy in type 1 and type 2 histology - Poster

SAN FRANCISCO, CA USA ( - Presented by Bernard J. Escudier, Sergio Bracarda, José Pablo Maroto Rey, Cezary Szczylik, Paul D. Nathan, Sylvie Negrier, Agnese Cattaneo, Claudia Weiss, Camillo Porta, and Viktor Gruenwald at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

gucancer 2014 RAPTOR Poster thumb

Institut Gustave Roussy, Villejuif, France; Medical Oncology, Department of Oncology. Ospedale San Donato, Arezzo, Italy; Institution Hospital Sant Pau, Barcelona, Spain; Military Institute of Medicine, Warsaw, Poland; Mount Vernon Cancer Centre, Northwood, United Kingdom; University of Lyon, Cancer Centre Leon Berard, Lyon, France; Novartis Farma S.p.A., Origgio, Italy; Novartis Pharma GmbH, Nuremberg, Germany; IRCCS San Matteo University Hospital Foundation, Pavia, Italy; Medical University of Hannover, Hannover, Germany